In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback ... for Pfizer-partnered prostate cancer therapy Xtandi ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

A non-surgical treatment for prostate cancer is proving a successful alternative to conventional surgery and radiotherapy. Based on the concept of cryotherapy, the new technique freezes away ...

Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.